SREBF1 and hypertriglyceridemia: A major drawback to the in vivo use of LXR agonists is the development of hypertriglyceridemia and hepatosteatosis via upregulation of the LXR target gene and lipogenic factor Srebp1c, in the liver.73, 74, 75